Acuta Capital Partners LLC Purchases Shares of 1,979,199 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Acuta Capital Partners LLC acquired a new position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,979,199 shares of the company’s stock, valued at approximately $807,000. Unicycive Therapeutics comprises approximately 0.7% of Acuta Capital Partners LLC’s holdings, making the stock its 27th biggest holding. Acuta Capital Partners LLC owned about 2.10% of Unicycive Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Unicycive Therapeutics in the first quarter worth $36,000. Bleakley Financial Group LLC purchased a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $33,000. Finally, Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at about $3,491,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $0.68 on Thursday. The firm has a market capitalization of $70.37 million, a P/E ratio of -0.61 and a beta of 2.29. Unicycive Therapeutics, Inc. has a one year low of $0.20 and a one year high of $1.82. The company’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.51.

Analyst Ratings Changes

A number of equities analysts recently issued reports on UNCY shares. HC Wainwright reissued a “buy” rating and issued a $2.50 price target on shares of Unicycive Therapeutics in a research note on Tuesday, November 12th. Benchmark reissued a “speculative buy” rating and issued a $3.00 target price on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $5.13.

Unicycive Therapeutics Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.